Evaluation of Experimental Autoimmune Uveitis in Mice Treated with FTY720


Autoria(s): COMMODARO, Alessandra Goncalves; PERON, Jean Pierre S.; LOPES, Camila Takao; ARSLANIAN, Christina; BELFORT JR., Rubens; RIZZO, Luiz Vicente; BUENO, Valquiria
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

20/10/2012

20/10/2012

2010

Resumo

PURPOSE. FTY720 (fingolimod) is an immunomodulatory drug capable of preventing T-cell migration to inflammatory sites by binding to and subsequently downregulating the expression of sphingosine-1 phosphate receptor 1 (S1P(1)) leading in turn to T-cell retention in lymphoid organs. Additional effects of FTY720 by increasing functional activity of regulatory T cells have recently been demonstrated, raising the conversion of conventional T cells into regulatory T cells and affecting the sequestration of regulatory T cells in normal mice. In this study, the action of FTY720 in the ocular autoimmune model in mice was investigated. METHODS. Mice were immunized with 161-180 peptide and pertussis toxin and were treated with 1 mg/kg/d FTY720 by gavage (7-21 days postimmunization [dpi]) or left untreated. Spleen cells, harvested 21 dpi, were cultured and assayed for cytokine production. Draining lymph node, spleen, and eye cells 21 dpi were assayed for quantification of T-cell populations. Disease severity was evaluated by histologic examination of the enucleated eyes at 21 and 49 dpi. In addition, anti-IRBP antibodies were analyzed by ELISA. RESULTS. FTY720 was effective in suppressing the experimental autoimmune uveitis score. Although there was a reduction in the number of eye-infiltrating cells, FTY did not prevent Treg accumulation at this site. FTY720 leads to a significant increase of CD4(+)IFN-gamma(+) and CD4(+)Foxp3(+) cell percentages in lymph nodes, suggesting that this site could be the source of Treg cells found in the eye. CONCLUSIONS. The data showed that treatment in vivo with FTY720 was able to suppress EAU in mice. These results are indicative of the possible therapeutic use of FTY720 in ocular autoimmune processes. (Invest Ophthalmol Vis Sci. 2010;51:2568-2574) DOI:10.1167/iovs.09-4769

FAPESP Fundacao de Amparo a Pesquisa do Estado de Sao Paulo[04/14727-0]

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

CNPq Conselho Nacional de Desenvolvimento Cientifico e Tecnologico

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Pan-American Ophthalmological Foundation[2007]

Pan-American Ophthalmological Foundation

FADA-Universidade Federal de Sao Paulo (UNIFESP)

FADA-Universidade Federal de Sao Paulo (UNIFESP)

Identificador

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, v.51, n.5, p.2568-2574, 2010

0146-0404

http://producao.usp.br/handle/BDPI/28271

10.1167/iovs.09-4769

http://dx.doi.org/10.1167/iovs.09-4769

Idioma(s)

eng

Publicador

ASSOC RESEARCH VISION OPHTHALMOLOGY INC

Relação

Investigative Ophthalmology & Visual Science

Direitos

restrictedAccess

Copyright ASSOC RESEARCH VISION OPHTHALMOLOGY INC

Palavras-Chave #RETINOID-BINDING PROTEIN #REGULATORY T-CELLS #ORAL TOLERANCE #IFN-GAMMA #GENETIC SUSCEPTIBILITY #FUNCTIONAL-ACTIVITY #DENDRITIC CELLS #MURINE MODEL #UVEORETINITIS #IMMUNOSUPPRESSANT #Ophthalmology
Tipo

article

original article

publishedVersion